Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial
暂无分享,去创建一个
Roger Paredes | Esteban Martinez | Bonaventura Clotet | R. Paredes | B. Clotet | E. Negredo | M. Plana | J. Gatell | J. Mallolas | E. Martinez | J. Blanco | M. Laguno | F. Vidal | X. Carné | M. Loncá | José A. Martínez | Elisa de Lazzari | Xavier Carne | Montserrat Plana | Jose M Gatell | Josep Mallolas | Jose A Martinez | Jose L Blanco | Jhon Rojas | Eugenia Negredo | Maria Casadella | Alexy Inciarte | Montserrat Laguno | Maria Martinez-Rebollar | Berta Torres | Montserrat Lonca | Amparo Tricas | Ana Rodriguez | Pilar Callau | Alberto Crespo | Sonsoles Sanchez | Francesc Vidal | E. De Làzzari | J. Rojas | M. Casadellà | B. Torres | A. Inciarte | M. Martínez-Rebollar | P. Callau | Alberto Crespo | A. Tricas | Ana Rodriguez | S. Sanchez | J. Martínez
[1] J. Gatell,et al. Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression. , 2016, Journal of Antimicrobial Chemotherapy.
[2] E. Martínez,et al. Posicionamiento de dolutegravir en el tratamiento de la infección por el VIH , 2015 .
[3] J. Casado,et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study , 2002, AIDS.
[4] C. Katlama,et al. Dolutegravir resistance mutations: lessons from monotherapy studies , 2018, Current opinion in infectious diseases.
[5] A. Kashuba,et al. Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir , 2013, Clinical Pharmacokinetics.
[6] J. Gatell,et al. Individual patient data meta-analysis of randomized controlled trials of dual therapy with a boosted PI plus lamivudine for maintenance of virological suppression: GeSIDA study 9717 , 2018, The Journal of antimicrobial chemotherapy.
[7] C. Fichtenbaum,et al. Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] C. Mussini,et al. Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients , 2017, BMC Infectious Diseases.
[9] N. Clumeck,et al. Effects of switching to protease inhibitor monotherapy on nucleoside analogue-related adverse events. , 2014, AIDS reviews.
[10] Eleni-Rosalina Andrinopoulou,et al. Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial. , 2017, The lancet. HIV.